読み込み中
NASDAQHealthcareBiotechnology
最新データ
$0.4713
+$0.003 · +0.64%
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
通常取引
$0.4713
+$0.003 · +0.64%
日中の時刻はETです。市場データは遅延する場合があります。
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
日中レンジ
現在 $0.4713
52週レンジ
現在 $0.4713
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
59
まちまち
リスク
84
極めて高いリスク
モメンタム
24
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
日中レンジ
現在 $0.4713
52週レンジ
現在 $0.4713
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 500万 USD | — | 66.8万 USD | — | — |
| 粗利益 | −500万 USD | — | −66.8万 USD | — | — |
| 研究開発 | 1.76億 USD | 2.01億 USD | 1.43億 USD | 1.05億 USD | 2.13億 USD |
| 販売・一般管理 | 6009.1万 USD | 6253.7万 USD | 4480.7万 USD | 3112.1万 USD | 2454.7万 USD |
| 営業費用 | 2.36億 USD | 2.63億 USD | 1.88億 USD | 1.36億 USD | 2.37億 USD |
| 受取利息 | 834.4万 USD | 1993.3万 USD | 1661.1万 USD | 456.1万 USD | — |
| 支払利息 | 321.9万 USD | — | — | — | — |
| 減価償却費と償却費 | 20.8万 USD | 63.1万 USD | 66.8万 USD | 59.4万 USD | 53.8万 USD |
| 営業利益 | −2.41億 USD | −2.63億 USD | −1.88億 USD | −1.36億 USD | −2.37億 USD |
| 純利益 | −2.37億 USD | −2.44億 USD | −2.36億 USD | −1.31億 USD | −2.37億 USD |
会社概要が更新されました 2026年10月8日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$4.50
上昇余地（854.81%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI456.93万0.00%2.3兆 USD0.03%$379.42-0.42%
Vanguard Extended Market ETFVXF149.77万0.00%954億 USD0.05%$231.34-0.92%
iShares Russell 2000 ETFIWM119.55万0.00%785.63億 USD0.19%$274.74-1.07%
Vanguard Russell 2000 ETFVTWO78.41万0.00%180億 USD0.06%$110.98-1.10%
iShares Russell 2000 Growth ETFIWO49.81万0.00%142.49億 USD0.24%$350.58-1.35%
iShares Biotechnology ETFIBB27.27万0.00%104.01億 USD0.44%$197.88-2.69%
Vanguard Health Care ETFVHT26.4万0.00%220億 USD0.09%$309.24-1.93%
Schwab U.S. Small-Cap ETFSCHA25.4万0.00%216.99億 USD0.03%$32.295-0.97%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Health Care ETFVHTSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
